Last reviewed 2026-04-20 · How we verify

TEV-48125 - 3

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Injection site pain
• Injection site induration
• Injection site erythema
• Nasopharyngitis
• Upper respiratory tract infection
• Injection site pruritus
• Injection site haemorrhage
• Sinusitis
• Influenza
• Bronchitis
• Urinary tract infection
• Migraine

Key clinical trials

• A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine (PHASE3)
• Fremanezumab Compassionate Use Program for Pediatric Patients
• Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine (PHASE3)
• A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH) (PHASE2)
• To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125 (PHASE1)
• Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine (PHASE3)
• An Efficacy and Safety Study of Fremanezumab in Adults With Migraine (PHASE3)
• Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.